These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 17635240)
21. Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Kobayashi M; Nukui A; Morita T Urol Int; 2008; 80(2):186-92. PubMed ID: 18362491 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml. Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Singer EA; Palapattu GS; van Wijngaarden E Cancer; 2008 Oct; 113(8):2053-7. PubMed ID: 18780337 [TBL] [Abstract][Full Text] [Related]
25. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. Goel T; Garg S Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015 [TBL] [Abstract][Full Text] [Related]
26. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Dai B; Ye DW; Kong YY; Shen YJ; Wang BH Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514 [TBL] [Abstract][Full Text] [Related]
27. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Kandirali E; Boran C; Serin E; Semercioz A; Metin A Urology; 2007 Oct; 70(4):743-7. PubMed ID: 17991548 [TBL] [Abstract][Full Text] [Related]
28. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417 [TBL] [Abstract][Full Text] [Related]
30. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]
31. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Xie W; Nakabayashi M; Regan MM; Oh WK Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608 [TBL] [Abstract][Full Text] [Related]
32. Renal cell carcinoma with non-Hodgkin's lymphoma infiltration: a case report. Sullu Y; Donmez G; Kandemir B; Gun S Pathol Res Pract; 2007; 203(8):625-7. PubMed ID: 17662539 [TBL] [Abstract][Full Text] [Related]
33. Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer? Beltrami P; Ruggera L; Cazzoletti L; Schiavone D; Zattoni F Prostate; 2008 Aug; 68(11):1241-7. PubMed ID: 18484098 [TBL] [Abstract][Full Text] [Related]
34. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353 [TBL] [Abstract][Full Text] [Related]
35. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062 [TBL] [Abstract][Full Text] [Related]
36. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience]. Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203 [TBL] [Abstract][Full Text] [Related]
37. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms. van Renterghem K; van Koeveringe G; Achten R; van Kerrebroeck P Urol Int; 2009; 83(1):60-5. PubMed ID: 19641361 [TBL] [Abstract][Full Text] [Related]
38. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691 [TBL] [Abstract][Full Text] [Related]
39. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy. Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991 [TBL] [Abstract][Full Text] [Related]
40. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]